# Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

> **NCT07551778** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **BOE Technology Group Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- Colorectal Cancer
- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** NK Cells
- **BIOLOGICAL:** NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy
- **BIOLOGICAL:** NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy

## Key facts

- **NCT ID:** NCT07551778
- **Lead sponsor:** BOE Technology Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-04
- **Final completion:** 2029-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551778, "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07551778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*